145 related articles for article (PubMed ID: 30212182)
21. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
[TBL] [Abstract][Full Text] [Related]
22. Reaching out for Sensitive Evaluation of the Mu Opioid Receptor in Vivo: Positron Emission Tomography Imaging of the Agonist [
Rafique W; Khanapur S; Spilhaug MM; Riss PJ
ACS Chem Neurosci; 2017 Sep; 8(9):1847-1852. PubMed ID: 28590714
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
24. PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age.
Vijay A; Cavallo D; Goldberg A; de Laat B; Nabulsi N; Huang Y; Krishnan-Sarin S; Morris ED
Neuropsychopharmacology; 2018 Dec; 43(13):2539-2547. PubMed ID: 30188515
[TBL] [Abstract][Full Text] [Related]
25. N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.
Béguin C; Potter DN; Dinieri JA; Munro TA; Richards MR; Paine TA; Berry L; Zhao Z; Roth BL; Xu W; Liu-Chen LY; Carlezon WA; Cohen BM
J Pharmacol Exp Ther; 2008 Jan; 324(1):188-95. PubMed ID: 17951511
[TBL] [Abstract][Full Text] [Related]
26. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
[TBL] [Abstract][Full Text] [Related]
27. The effects of kappa-opioid receptor ligands on prepulse inhibition and CRF-induced prepulse inhibition deficits in the rat.
Tejeda HA; Chefer VI; Zapata A; Shippenberg TS
Psychopharmacology (Berl); 2010 Jun; 210(2):231-40. PubMed ID: 20232058
[TBL] [Abstract][Full Text] [Related]
28. Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: contingent vs. non-contingent administration.
Townsend EA
Psychopharmacology (Berl); 2021 Apr; 238(4):1017-1028. PubMed ID: 33404739
[TBL] [Abstract][Full Text] [Related]
29. Role for kappa-opioid system in stress-induced cocaine use uncovered with PET.
Blevins D; Martinez D
Neuropsychopharmacology; 2020 Jan; 45(1):233-234. PubMed ID: 31501528
[No Abstract] [Full Text] [Related]
30. Fluorine-18-Labeled Antagonist for PET Imaging of Kappa Opioid Receptors.
Cai Z; Li S; Pracitto R; Navarro A; Shirali A; Ropchan J; Huang Y
ACS Chem Neurosci; 2017 Jan; 8(1):12-16. PubMed ID: 27741398
[TBL] [Abstract][Full Text] [Related]
31. Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates.
Hume SP; Lingford-Hughes AR; Nataf V; Hirani E; Ahmad R; Davies AN; Nutt DJ
J Pharmacol Exp Ther; 2007 Aug; 322(2):661-7. PubMed ID: 17488881
[TBL] [Abstract][Full Text] [Related]
32. Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors.
Patkar KA; Wu J; Ganno ML; Singh HD; Ross NC; Rasakham K; Toll L; McLaughlin JP
J Pharmacol Exp Ther; 2013 Sep; 346(3):545-54. PubMed ID: 23853171
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat.
Ozaki N; Sengupta JN; Gebhart GF
J Neurophysiol; 2000 Apr; 83(4):2209-16. PubMed ID: 10758129
[TBL] [Abstract][Full Text] [Related]
34. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
Rorick-Kehn LM; Witcher JW; Lowe SL; Gonzales CR; Weller MA; Bell RL; Hart JC; Need AB; McKinzie JH; Statnick MA; Suico JG; McKinzie DL; Tauscher-Wisniewski S; Mitch CH; Stoltz RR; Wong CJ
Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25637376
[TBL] [Abstract][Full Text] [Related]
35. Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.
Zamarripa CA; Naylor JE; Huskinson SL; Townsend EA; Prisinzano TE; Freeman KB
Psychopharmacology (Berl); 2020 May; 237(5):1471-1480. PubMed ID: 32006048
[TBL] [Abstract][Full Text] [Related]
36. N-[
Schmitt S; Delamare J; Tirel O; Fillesoye F; Dhilly M; Perrio C
Nucl Med Biol; 2017 Jan; 44():50-61. PubMed ID: 27821345
[TBL] [Abstract][Full Text] [Related]
37. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay.
Wettstein JG; Grouhel A
Pharmacol Biochem Behav; 1996 Feb; 53(2):411-6. PubMed ID: 8808151
[TBL] [Abstract][Full Text] [Related]
38. Molecular Interaction Between Butorphanol and κ-Opioid Receptor.
Ji J; Lin W; Vrudhula A; Xi J; Yeliseev A; Grothusen JR; Bu W; Liu R
Anesth Analg; 2020 Sep; 131(3):935-942. PubMed ID: 32701545
[TBL] [Abstract][Full Text] [Related]
39. [11C]-methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl)-methyl]-1- piperazinecarboxylate ([11C]GR89696): synthesis and in vivo binding to kappa opiate receptors.
Ravert HT; Mathews WB; Musachio JL; Scheffel U; Finley P; Dannals RF
Nucl Med Biol; 1999 Oct; 26(7):737-41. PubMed ID: 10628552
[TBL] [Abstract][Full Text] [Related]
40. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro.
Feng J; Kendig JJ
Pain; 1996 Aug; 66(2-3):343-9. PubMed ID: 8880858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
